# The importance of early biomarkers in the identification of neurodegenerative disorders

## TL;DR

This study tracks iRBD patients over three years to identify early biomarkers that predict progression to Parkinson's or other neurodegenerative diseases.

## Contribution

The study identifies STAT1, GATA3, and FOXP3 mRNA levels in CD4+ T cells as potential early biomarkers for predicting phenoconversion in iRBD patients.

## Key findings

- iRBD patients were monitored for three years to assess phenoconversion to Parkinson's disease.
- STAT1, GATA3, and FOXP3 mRNA levels in CD4+ T cells were found to be predictive of phenoconversion.
- The study supports the use of transcription factor mRNA levels as early biomarkers for neurodegenerative disorders.

## Abstract

In this datanote we presented the data of 31 iRBD (idiopathic Rapid eye movement (REM) sleep Behaviour Disorder) patients studied throughout three years to assess their eventual phenoconversion to Parkinson’s disease and other established neurodegenerative conditions.

iRBD is a prodromal condition involved in the development of neurological pathologies such as Parkinson’s disease. In a previous study we evaluated transcription factor mRNA levels in CD4+ T cells as predictive biomarkers of phenoconversion in iRBD. We demonstrated that among the transcription factors mRNA levels analysed, STAT1, GATA3 and FOXP3 mRNA levels in CD4+ T cells may be used to predict phenoconversion.